John Flavin’s Post

Unlocking innovation – how to take your research idea from concept to reality! We invited researchers and entrepreneurs in Norway to our drug discovery seminar co-hosted with ShareLab at Forskningsparken - Oslo Science Park.  We were thrilled to have Georg Vo Beiske at Tribune Therapeutics share his experience with us.    During the seminar, we also tackled several interesting questions from the audience. One of those were - toxicity studies versus compound optimization, at which end do you start? Focus on the big picture and use a balanced approach. The winner is likely not the one with the absolute best solubility or potency. A compound with a good overall profile can go far too! Our seminar also emphasized the importance of designing your "killer" experiment early in the process. How will your compound compare to the treatments available on the market? By anticipating the toughest questions from potential investors and stakeholders, you can ensure your drug stands out from the rest!

𝑷𝒖𝒃𝒍𝒊𝒄 𝑷𝒓𝒊𝒗𝒂𝒕𝒆 𝑷𝒂𝒓𝒕𝒏𝒆𝒓𝒔𝒉𝒊𝒑𝒔 – 𝒑𝒂𝒗𝒊𝒏𝒈 𝒕𝒉𝒆 𝒘𝒂𝒚 𝒇𝒐𝒓 𝒄𝒐𝒍𝒍𝒂𝒃𝒐𝒓𝒂𝒕𝒊𝒗𝒆 𝒊𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏 🤝 On the occasion of the European Biotechnology Revue (EBR) spring issue, Julia Schaft gave an interview on the emergence and further development of public-private partnerships. Julia explains in the interview: 💡Most common barriers of industry-academia partnerships and how they can be overcome 💡How these partnerships will develop in the future 💡How these partnerships can be encouraged at an international level and 💡What can be done to advance the growth of Life Sciences hubs 👉 Read the whole article: https://bit.ly/3Turb89 Samedan Ltd; BioMed X Institute;

New VIB spinoff Tanai Therapeutics will address an increasingly urgent societal issue: Obesity. While there has been a lot of talk about the obesity space in the past few months, at its core, obesity presents an incredible challenge for our health care systems. By 2035, the economic impact of persons with a high BMI could reach over $4 trillion annually. That is why, together with lead investor V-Bio Ventures and Qbic Fund | Venture Capital, VIB created Tanai Therapeutics in hopes of developing a sustainable solution to obesity. Interested and want to learn more about Tanai Therapeutics? Read the full story here 👇 https://lnkd.in/eu43TJnw

🌱 Exciting TED Talk Alert! 🎙️ Dr. Michael Jewett, a Professor of Bioengineering at Stanford, shares his vision for the future of biotechnologies. Can we create equitable and distributed biotech for the greater good? What if we re-thought how biotechnologies are created and shared? In this thought-provoking TED Talk, you’ll learn how engineered biological systems are opening access to medicines, diagnostics, and more. 🧬 #TEDTalk #Biotechnology #SyntheticBiology #Innovation #FutureofScience

Exciting Times for European Biotech! The European biotech landscape is buzzing with innovation and groundbreaking projects! As we steer into the future, we're witnessing remarkable advancements that are set to shape the healthcare and technology sectors. Recently, I came across a news article highlighting the launch of several high-impact biotech projects across Europe. One notable initiative is the comprehensive research into gene editing led by a consortium of biotech firms from the UK, Germany, and France. This project aims to revolutionise treatments for genetic disorders, offering hope to millions. Another milestone is a major collaboration between Nordic countries focusing on sustainable biomanufacturing, which promises to reduce the carbon footprint of pharmaceutical production. These projects not only demonstrate Europe's commitment to scientific excellence but also underline the vision for a healthier, sustainable future. Having spent years in the biotech industry, I can personally attest to the immense potential of these collaborations. They reflect the collective expertise and a shared passion for pushing the boundaries of what's possible. The support from the European Union, in terms of funding and policy frameworks, has been instrumental in accelerating these innovations. It's an inspiring time to be part of this community, and I look forward to seeing the tangible benefits these projects will bring. How do you see these developments shaping the future? Drop your thoughts below! #Biotech #Innovation #EuropeanScience #HRS #Science

A 2018 article from Nature found that more than 50% of biological research may not be reproducible. This problem is especially evident in longevity science, and is one of the largest hurdles to innovation. Before investing in a new company, Ichor makes a point to directly validate findings by replicating results. Longevity Technology released an interview with CEO Kelsey Moody today about why this is important, you can check it out here: https://lnkd.in/eyJQHWiH #biotech #innovation #ichorlifesciences #drugdevelopment

"🔬✨ ProNet Biotech is at the forefront of yeast technology innovation, breaking boundaries and transforming scientific breakthroughs into real-world applications. 🌐 From our cutting-edge research in Molecular Pairing to Antibody Discovery, Protein Synthesis, and Enzyme Engineering, we're shaping the future of biosynthesis. 🚀 Join us on the journey towards a new era in life science and biotechnology! #ProNetBiotech #Innovation #BiosynthesisRevolution"

🎉 We're back after our summer break, so why not join us for our free-to-attend webinar on Wednesday 27 September 2023? Discover the cutting-edge world of genetic engineering, biomaterial design, and sequencing, all crucial components for growth media and cell lines. 🧬 The success of cultivated meat hinges on improving cell line performance and advancing growth media composition. There are numerous future technologies that have the potential to make growth media and cell lines more cost-effective, including next-generation growth media, serum-free and xeno-free media, genetic engineering and cell line optimization, bioprocess optimization, and even automation and robotics. But their full-scale implementation and commercialization may take time. During this webinar, our superb panelists will look at these innovations and ask how we can speed things up with Ramiro Alberio, Founder of PluriCells, Cai Linton, CEO of Multus, and Rowan Rimington, Head of Cell Biology at Ivy Farm Technologies, and Catherine Elton, CEO of Qkine🌍🌱🥩 🔬 Whether you're a scientist, a student, or simply curious about the latest developments in biotechnology, this webinar is not to be missed! Register now via the link below and secure your virtual seat at this must-attend event! Don't wait, spots are limited! 👉 https://hubs.ly/Q021hJTF0 👈 🎯 Don't miss out on this incredible opportunity. See you there! #proteinproduction #alternativeproteins #foodtech

Startups Exploring Diversity in Genetics and Biotechnology Research This week we spotlight startups helping close the diversity gap in healthcare. The journey towards achieving diversity in genetics and biotechnology research is critical and ongoing. Startups like Yemaachi Biotech, Hurone AI and Acclinate are pioneering innovative solutions to address the lack of diversity in genomics, biotechnology, and clinical trial research. Through their groundbreaking technologies, collaborative initiatives, and inclusive approaches, these startups are revolutionising the landscape of healthcare equity and diversity. By Henry Duah Read the full article: https://lnkd.in/ezAhCkVn Get innovation insights from The FutureList weekly. Subscribe to our newsletter here: https://bit.ly/3DVZexv #cancercare #genomics #biotechnology #clinicaltrials #artificialintelligence

This weekend at Aspen Ideas: Health, BioAge CEO Kristen Fortney, PhD joins thought leaders in longevity and rejuvenation biotech to discuss the research and technologies that are bringing us closer to extending human healthspan. On the agenda: Today, scientists are deeply engaged in efforts to slow aging and eliminate age-related diseases by editing genes, reprogramming cells, and developing novel molecular therapeutics. AI-driven technologies are sorting through existing compounds to repurpose them for longevity. Biotech companies are developing therapies that target metabolic aging to improve the effectiveness of new weight-loss drugs. Mission-driven entrepreneurs are attracting funding for all of this so promising longevity work can move swiftly from the lab to the clinic. How do all of these rapidly progressing parts fit together to define the future of human health? Joining Kristen on stage will be Laura Deming, venture partner and co-founder of age1 and CEO of Cradle, and Richard Klausner, founder and chief scientist of Altos Labs. Allison Aubrey, food and health correspondent for NPR News, will moderate. https://lnkd.in/gqiXdfUa #AspenIdeasHealth creates a forum for experts and visionaries to share knowledge and experience, offering a unique opportunity to turn ideas into action and forge a path toward better health for all.